Saturday 17 October 2026
Export CPHI’s income statement to Excel — free account
China Pharma Holdings, Inc.
CPHI Healthcare Drug Manufacturers Specialty & Generic
China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.
0.71
0.02
−2.74%
Follow CPHI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 4 | 6 | 5 | 6 | 2 | 2 | 5 | 1 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.70 | 0.56 | 0.92 | 0.96 | 1.81 | 2.30 | 0.58 | 0.29 | 0.89 | 1.25 |
Altman Z-Score |
0.75 | (0.34) | (0.24) | (3.93) | (1.25) | (1.26) | (3.28) | (3.39) | (4.66) | (2.16) |
P/FCF ratio |
14.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.08 | 1.22 | (0.03) | (10.55) | (6.52) | (5.52) | (10.14) | (8.36) | (11.34) | (3.85) |
P/Operating CF |
7.39 | 7.91 | 12.96 | (473.48) | 58.60 | (111.82) | 8.09 | (91.05) | 13.44 | 34.16 |
Beneish M-Score |
(3.79) | (4.52) | (4.34) | (7.87) | (3.55) | (0.63) | — | — | — | — |
P/B ratio |
0.19 | 0.17 | 0.38 | 1.13 | 2.45 | 3.68 | 1.10 | 0.27 | 0.52 | 0.23 |
Price to Tangible BV |
0.19 | 0.17 | 0.38 | 1.16 | 2.51 | 3.77 | 1.91 | 0.48 | 3.82 | 0.00 |
EV/Sales |
1.11 | 1.05 | 1.25 | 1.24 | 2.19 | 2.78 | 1.22 | 0.43 | 1.28 | 1.97 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 235.91 | 56.11 | 0.00 | 1,657.33 | 0.00 | 0.00 |
EV/Operating CF |
5.95 | 16.47 | 8.18 | 22.25 | (563.83) | (107.21) | (24.12) | (4.26) | (14.23) | 54.92 |
EV/FCF |
22.38 | (11.28) | (151.42) | (9.27) | (8.39) | (11.21) | (3.60) | (1.13) | (2.47) | (184.67) |
Quick Ratio |
0.77 | 0.57 | 0.36 | 0.19 | 0.14 | 0.54 | 0.20 | 0.32 | 0.18 | 0.09 |
Current Ratio |
1.69 | 1.33 | 0.87 | 0.56 | 0.47 | 0.86 | 0.47 | 0.88 | 0.65 | 0.32 |
Net Debt/EBITDA |
(1.25) | (0.42) | (0.57) | (0.18) | 41.80 | 9.70 | (0.47) | 529.33 | (0.92) | (0.98) |
Debt/Assets |
12.84% | 15.38% | 14.42% | 19.34% | 24.82% | 42.29% | 13.73% | 14.83% | 16.17% | 6.38% |
Debt/Equity |
0.17 | 0.21 | 0.22 | 0.47 | 0.65 | 1.59 | 0.57 | 0.33 | 0.31 | 0.09 |
Asset Turnover |
0.18 | 0.19 | 0.23 | 0.32 | 0.50 | 0.44 | 0.40 | 0.41 | 0.29 | 0.18 |
Operating CF/Net income |
(0.32) | (0.04) | (0.18) | (0.03) | 0.01 | 0.07 | 0.10 | 0.23 | 0.09 | (0.05) |
Capex/Depreciation |
(0.06) | (0.04) | (0.02) | (0.05) | (0.32) | (0.13) | (0.15) | 0.00 | (0.11) | (0.09) |
Interest Coverage |
(9.60) | (34.64) | (23.15) | (63.44) | (8.76) | (5.28) | (8.17) | (8.25) | (29.78) | (31.76) |
| (13.96%) | (37.81%) | (29.34%) | (104.99%) | (33.25%) | (48.49%) | (77.08%) | (52.43%) | (62.31%) | (20.91%) | |
| (10.49%) | (27.84%) | (20.41%) | (61.24%) | (13.23%) | (15.53%) | (19.65%) | (17.98%) | (30.21%) | (13.89%) | |
ROIC |
(7.81%) | (23.58%) | (19.06%) | (103.64%) | (13.17%) | (16.79%) | (47.32%) | (20.46%) | (30.16%) | (8.31%) |
Return on Tangible Assets |
(28.62%) | (72.46%) | (59.76%) | (174.74%) | (30.23%) | (28.66%) | (124.22%) | (49.05%) | (151.01%) | 481.51% |
Average Days of Receivables |
99.02 | 67.85 | 32.18 | 22.79 | 17.79 | 28.16 | 20.30 | 34.48 | 21.15 | 25.60 |
Research and Development Expense of Revenue |
2.35% | 0.68% | 1.40% | 2.10% | 3.48% | 3.31% | 2.29% | 3.42% | 6.27% | 6.78% |
Selling, General and Administrative Expense of Revenue |
40.48% | 41.48% | 41.90% | 42.49% | 37.16% | 32.63% | 36.56% | 32.04% | 51.09% | 68.22% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.10 | 0.20 | 0.45 | 0.78 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.16% | 0.97% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.19) | (0.62) | (0.57) | (0.71) | (0.40) | (0.34) | (1.59) | (1.49) | (0.96) | (1.14) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(88.00%) | (258.82%) | (91.05%) | (200.00%) | (14.41%) | (16.67%) | (83.94%) | (145.03%) | (117.39%) | (61.98%) |
Free Cash Flow Yield |
7.06% | (16.57%) | (0.90%) | (13.96%) | (14.49%) | (10.78%) | (58.02%) | (130.22%) | (58.18%) | (0.85%) |
Revenue per Share |
178.56 | 151.52 | 141.41 | 125.27 | 124.62 | 104.46 | 77.11 | 20.72 | 2.59 | 0.97 |
Operating CF per Share |
33.21 | 9.65 | 21.58 | 6.98 | (0.49) | (2.71) | (3.90) | (2.07) | (0.23) | 0.03 |
Capex per Share |
(2.22) | (1.57) | (0.59) | (1.56) | (9.95) | (4.75) | (3.82) | (0.03) | (0.17) | (0.03) |
Free Cash Flow per Share |
30.99 | 8.08 | 21.00 | 5.42 | (10.43) | (7.45) | (7.72) | (2.10) | (0.40) | 0.00 |
Cash per Share |
43.06 | 31.88 | 28.45 | 14.11 | 11.60 | 53.63 | 19.45 | 4.40 | 0.37 | 0.08 |
Shareholders Equity per Share |
675.56 | 493.94 | 346.32 | 105.94 | 91.79 | 65.20 | 40.82 | 22.03 | 4.44 | 5.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
675.56 | 493.94 | 346.32 | 105.94 | 91.79 | 65.20 | 40.82 | 22.03 | 4.44 | 5.30 |
Free Cash Flow |
2.70 | 0.70 | 1.83 | 0.47 | (0.91) | (0.69) | (0.81) | (0.71) | (0.70) | 0.01 |
Working Capital |
7.12 | 3.06 | (1.30) | (4.47) | (6.08) | (1.42) | (6.77) | (0.82) | (1.75) | (5.05) |
Capital Expenditures |
(0.19) | (0.14) | (0.05) | (0.14) | (0.87) | (0.44) | (0.40) | (0.01) | (0.29) | (0.14) |
Net Current Asset Value |
(2.09) | (4.59) | (6.43) | (7.42) | (7.79) | (7.54) | (7.53) | (3.02) | (3.87) | (5.91) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | 0.08 | 0.05 | 0.05 | 0.00 | 0.06 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.14 | 0.17 | 0.18 | 0.17 | 0.25 | 0.27 | 0.39 | 0.55 | 0.36 |
Cash ROIC |
3.71% | 1.28% | 4.67% | 3.20% | (6.38%) | (3.35%) | (9.25%) | (6.25%) | (6.46%) | 0.04% |
Accounts Receivable Turnover |
3.21 | 3.96 | 6.96 | 12.35 | 17.94 | 15.14 | 13.57 | 12.60 | 9.79 | 14.99 |
Accounts Payable Turnover |
4.49 | 5.11 | 9.41 | 7.78 | 6.85 | 8.60 | 10.79 | 8.93 | 10.94 | 7.66 |
Inventory Turnover |
1.46 | 1.57 | 1.81 | 2.18 | 2.44 | 2.64 | 2.74 | 2.18 | 2.17 | 2.20 |
Average Days of Payables |
90.43 | 38.77 | 37.39 | 52.82 | 50.56 | 36.40 | 28.32 | 48.37 | 12.61 | 76.06 |
Days of Inventory on Hand |
216.04 | 217.67 | 178.17 | 138.74 | 151.72 | 131.18 | 125.14 | 186.82 | 126.97 | 138.40 |
Average Receivables |
4.84 | 3.34 | 1.77 | 0.88 | 0.61 | 0.64 | 0.60 | 0.56 | 0.46 | 0.28 |
Average Payables |
2.75 | 2.10 | 1.10 | 1.21 | 1.30 | 1.08 | 0.80 | 0.82 | 0.60 | 0.56 |
Average Inventory |
8.49 | 6.86 | 5.73 | 4.32 | 3.65 | 3.52 | 3.14 | 3.34 | 3.00 | 1.94 |
Average Assets |
87.52 | 69.24 | 52.67 | 33.81 | 21.68 | 21.88 | 20.22 | 17.13 | 15.68 | 22.94 |
Average Common Equity |
65.78 | 50.99 | 36.64 | 19.72 | 8.62 | 7.01 | 5.15 | 5.87 | 7.60 | 15.24 |
Columns are period end dates